Keyword: Merck KGaA

Syndax’s entinostat missed its primary endpoints in two phase 1b/2 trials combining it with anti-PD-1 drugs from Genentech and Merck KGaA and Pfizer.

GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout.

Merck, which partnered with Pfizer on Bavencio, went to another Big Pharma for developmental work on a next-generation I-O drug to take on Keytruda.

Merck KGaA and Tencent will work to develop AI-based platforms to help increase access to healthcare services and promote disease awareness.

Merck licensed the drugs for $230 million upfront two years ago but has now granted Vertex the right to use them in certain gene-editing applications. 

Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.

Xenotransplantation firm eGenesis hires new R&D head; Relay adds execs to chemistry, R&D; and Navidea brings on new CMO focused on imaging.

Merck KGaA is launching a new joint venture with the tech firm Palantir, built around a collaboration platform for cancer research and discovery.

Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.

Merck KGaA has tapped digital diabetes platform provider GlucoMe for a pilot collaboration in five hospitals across Vietnam.